Webinars

New Approaches to Unintended Pregnancy Prevention: The Continued Need to Educate Clinicians and Pharmacists about Emergency Contraception

This is an internet-based activity that should take one hour to complete. To receive continuing education credit, learners should 1) take the pre-test 2) review the webinar and 3) complete the post-test.

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Counsel patients of reproductive age (and their partners) on the appropriate use of EC during routine and emergency visits.
• Facilitate patients’ access to EC by providing them with accurate information about how, where, and when to get and use EC and/or advanced prescriptions.

Accreditation Information

Physicians: The Association of Reproductive Health Professionals is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ARHP designates this internet enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Nurses: This activity has been approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health for up to 1.0 contact hours, including up to 0.5 pharmacology hours. Credit can be applied toward the nursing continuing education requirements of most professional organizations and State Boards of Nursing.

Pharmacists: The Association of Reproductive Health Professionals (ARHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hour of continuing education credit.

Others: A certificate of attendance will be issued indicating that this activity is accredited for 1 hour of AMA PRA Category 1 Credit^TM.

Sponsoring Information

This program is sponsored by the Association of Reproductive Health Professionals.

Funding Information

This project is funded through an educational grant from Watson Pharma, Inc.

**Funding for the 12/14/11 webinar has been provided by the National Campaign to Prevent Teen and Unplanned Pregnancy and its Bedsider program.

Disclosure Information

All individuals in a position to influence the content of this activity must disclose relevant financial relationship(s) with commercial interests and the nature of the relationship. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.

Target Audience

The intended audiences for this activity are clinicians providing women’s primary and reproductive health care, including physicians, physician assistants, nurse practitioners, and nurse-midwives practicing in obstetric/gynecology, family and internal medicine, and related settings.

Disclosures

All individuals in a position to influence the content of this activity must disclose relevant financial relationship(s) with commercial interests and the nature of the relationship. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.

• Suzanne Reiter, MM, MSN, WHNP-BC, SANE-A, FAANP(Planner) – consultant/speaker for Teva, Bayer, and Merck
• James Trussell, BPhil, PhD (Planner) – Consultant for Bayer Health Economics Unit, Berlin and served as chair of the DSMB for the two most recent trials of ulipristal acetate
• Don Downing, RPh (Planner), Eleanor Bimla Schwarz, MD, MS (Planner), Aleya Horn Kennedy, MPP (ARHP Program Manager), Deborah Kurnik, MBA (Consulting Writer), Beth Jordan Mynett, MD (ARHP Medical Director), Amy Swann, MA (ARHP Vice President) have nothing to disclose